Stability and sterility of a recombinant factor VIII concentrate (Bioclate(TM)) prepared for continuous infusion prophylaxis

被引：0
|
作者：
Belgaumi, AF
Patrick, CC
Tonkel, S
Deitcher, SR
Jude, S
机构：
[1] CHILDRENS RES HOSP, MEMPHIS, TN USA
[2] UNIV TENNESSEE, MEMPHIS, TN USA
来源：
THROMBOSIS AND HAEMOSTASIS | 1997年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：P2092 / P2092
页数：1
相关论文
共 50 条
  • [31] Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate®):: a prospective pharmacovigilance study
    Ewenstein, BM
    Gomperts, ED
    Pearson, S
    O'Banion, ME
    HAEMOPHILIA, 2004, 10 (05) : 491 - 498
  • [32] In vitro evaluation of B-domain deleted recombinant factor VIII (ReFacto®) stability during simulated continuous infusion administration
    Neidhardt, E
    Koval, R
    Burke, E
    Warne, N
    HAEMOPHILIA, 2005, 11 (04) : 319 - 325
  • [33] Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors
    Rubinger, M
    Houston, DS
    Schwetz, N
    Woloschuk, DMM
    Israels, SJ
    Johnston, JB
    AMERICAN JOURNAL OF HEMATOLOGY, 1997, 56 (02) : 112 - 118
  • [34] Factor VIII pharmacokinetics: Intermittent infusion versus continuous infusion
    Morfini, M
    Messori, A
    Longo, G
    BLOOD COAGULATION & FIBRINOLYSIS, 1996, 7 : S11 - S14
  • [35] Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates
    Dingli, D
    Gastineau, DA
    Gilchrist, GS
    Nichols, WL
    Wilke, JL
    HAEMOPHILIA, 2002, 8 (05) : 629 - 634
  • [36] Previously untreated patients and recombinant factor VIII concentrate studies
    Pasi, KJ
    BLOOD COAGULATION & FIBRINOLYSIS, 1997, 8 : S29 - S32
  • [37] EVALUATION OF FACTOR-VIII PHARMACOKINETICS IN HEMOPHILIA PATIENTS AFTER FACTOR-VIII CONCENTRATE INFUSION
    TAPONBRETAUDIERE, J
    GAZENGEL, C
    FISCHER, AM
    TORCHET, MF
    GUERDER, C
    JOSSO, F
    THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 210 - 210
  • [38] Rationale and indications for continuous infusion of antihemophilic factor (factor VIII)
    Goldsmith, JC
    BLOOD COAGULATION & FIBRINOLYSIS, 1996, 7 : S3 - S6
  • [39] In-vitro stability of B-domain deleted recombinant factor VIII in syringe-based continuous infusion devices.
    Woloschuk, DMM
    Dyck, JM
    Israels, SJ
    Toogood, P
    BLOOD, 2004, 104 (11) : 78B - 78B
  • [40] Determination of the factor VIII plasma activity of hemophilia a patients treated with a new recombinant factor VIII concentrate
    von Pape, KW
    Klamroth, R
    Kyank, U
    Bohner, J
    35TH HEMOPHILIA SYMPOSIUM, 2006, : 153 - +
12345